PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

This study is testing PLX038, a new long-acting camptothecin chemotherapy drug, in women with platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. "Platinum-resistant" means the cancer stopped responding to standard platinum-based chemotherapy within 6 months of completing it, which narrows treatment options significantly. **You may be eligible if...** - You are 18 or older with confirmed high-grade serous ovarian, fallopian tube, or primary peritoneal carcinoma - Your cancer is platinum-resistant (progressed within 6 months of platinum-based chemotherapy) - You have measurable disease visible on imaging - Your kidney, liver, and blood count levels are adequate for treatment **You may NOT be eligible if...** - Your cancer is a different histology (not high-grade serous) - You have been previously treated with camptothecin-class drugs or certain other overlapping agents - You have significant nerve damage, serious heart problems, or other major organ issues Talk to your doctor to see if this trial is right for you.